A blood based entire body screen to find HPV induced cancer early - all within minutes and by using just one drop of blood
Rapid test for detecting HPV16 induced carcinomas early. Easy to use in doctor's practice.
Clinical specificity > 99%
Learn more about screening for HPV induced cancer in the white paper series "Guidelines for identifying high-risk patients"
Find relevant resources about HPV and cancer
Moving from cell to blood based HPV cancer screening.
Abviris offers a new patented generation of Immune Oncology Diagnostics for early detection of HPV induced cancer, allowing a blood based entire body screen within minutes just using one drop of blood.
News
Investors Convinced of Potential and Importance of a Novel Cancer Management Concept
Abviris GmbH Obtains Almost 3 Million Euros in Series A Financing Abviris GmbH commenced market entry in Germany after successful test-marketing phase (450 customers, 300,000 € revenues) and, respective clinical trials. Initial positioning is targeting screening for HPV induced tumours of head and neck and the anogenital region. Funds raised in round A reveal that …
Tumour marker for the early detection and therapy of HPV-induced anal cancer for HIV+ patients
A pilot study has compared serum samples of HIV+ patients before and after treatment of an HPV induced anal carcinoma using the Prevo-Check®. Prevo-Check® has been confirmed as a high quality test for the early detection and therapy of HPV induced anal cancer for HIV+ patients. Study participants showing a high Prevo-Check® result developed anal …
Abviris and Mayo Clinic sign cooperation for research into HPV induced cancer diagnostics
Rochester, MN (USA) / Ahrensburg, Germany: Mayo Clinic and Abviris Deutschland GmbH have successfully signed a cooperation agreement for preclinical research into the diagnostics of HPV induced cancer. Mayo Clinic is one of the leading healthcare and medical research centers of the world. HPV and cancer HPV is responsible for 5% of all cancers, men …
